Abstract
Gram-positive bacteria are prominent causes of acute and chronic wound infection, yet treatment failure reflects more than conventional antimicrobial resistance. Persistent inflammation, polymicrobial ecology, necrotic tissue, inadequate source control, and biofilm-associated physiological tolerance all influence outcome. This structured narrative review integrates wound-healing biology with the pathogenesis of Staphylococcus aureus, Enterococcus spp., Streptococcus pyogenes, and Clostridium perfringens; distinguishes heritable resistance from biofilm tolerance; and critically appraises current management. Major resistance pathways include PBP2a-mediated β-lactam resistance, van-mediated glycopeptide resistance, active efflux, drug-inactivating enzymes, and ribosomal modification. Biofilms add spatially heterogeneous growth, persister cells, matrix binding, and altered host responses, so planktonic susceptibility results may not predict eradication. Clinically, diagnosis should be based on signs of infection and wound depth rather than culture alone, with tissue sampling after cleansing and debridement preferred when microbiology will change management. Urgent source control is central to abscesses, necrotizing infection, ischemic or devitalized tissue, and infected implants. Systemic antibiotics remain essential for spreading or deep infection, while topical antiseptics, antimicrobial peptides, photodynamic therapy, cold atmospheric plasma, phages, antibiofilm agents, and local delivery platforms are adjunctive or emerging approaches. Most innovative technologies remain supported mainly by in vitro or animal evidence; clinical adoption therefore requires standardized infected-wound models, safety assessment, and trials with infection-specific outcomes. Effective care is multimodal, combining diagnosis, debridement, perfusion and metabolic optimization, targeted antimicrobial therapy, local wound management, and stewardship.